Kreido’s STT® Reactor System to Be Utilized by Huntsman
News Oct 07, 2005
Kreido Laboratories has announced that Huntsman has purchased its STT® Reactor System.
Kreido Laboratories has pioneered a system for the manufacturing of chemicals, pharmaceuticals and other biological products.
The STT® system is designed to improve selectivity, increase yields and initiate chemistries.
The technology improves the efficiency, quality and speed of many chemical processes and facilitates continuous manufacturing.
The Huntsman transaction represents Kreido™s entry into the European marketplace.
Kreido has successfully applied the STT® Reactor System to the manufacturing of chemicals.
“We believe Huntsman will greatly benefit from our technology, as the systems ability to mitigate mass transfer limitations and accelerate reactions is well known,” said Kreido Laboratories Managing Director Ben Binninger.
“Numerous STT® Reactor Systems are already operating in the United States, and we are certainly delighted to expand our reach into Europe.”
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018